03/06/23 4:05 PMNasdaq : APLS Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to 6 new employees with a grant date of March 1, 2023, as equityRHEA-AIvery positive
03/01/23 7:00 AMNasdaq : APLS conferencesApellis Pharmaceuticals to Present at Upcoming Investor ConferencesApellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will participate in the following March investor conferences: Cowen 43rd Annual Healthcare Conference:RHEA-AIneutral
02/27/23 5:19 PMNasdaq : APLS offeringApellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional SharesApellis Pharmaceuticals, Inc., (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its previously announced underwritten public offering of common stock and pre-funded warrants, including theRHEA-AIneutral
02/22/23 9:48 PMNasdaq : APLS offeringApellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsApellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the pricing of its underwritten public offering of 3,174,603 shares of its common stock at a public offering price of $63.00RHEA-AIneutral
02/22/23 7:22 AMNasdaq : APLS offeringApellis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsApellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced that it has commenced an underwritten public offering of $300 million of its common stock (or pre-funded warrants toRHEA-AIneutral
02/21/23 4:13 PMNasdaq : APLS earningsApellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial ResultsSYFOVRE™ (pegcetacoplan injection) approved in the U.S. as the first and only treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) EU marketing authorization application for intravitreal pegcetacoplan validated by the European Medicines Agency; decision byRHEA-AIvery positive
02/17/23 4:06 PMNasdaq : APLS fda approvalFDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness SYFOVRE slowed GA progression with increasing effects over time Approved for all patients with GA, with dosing flexibility every 25 to 60 days Well-demonstrated safety profile following ~12,000 injections over 24 months Conference call today at 4:30 p.m. ET A Media Snippet accompanying thisRHEA-AIneutral
02/13/23 4:05 PMNasdaq : APLS Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to 8 new employees with a grant date of February 1, 2023, as equityRHEA-AIvery positive
01/05/23 7:00 AMNasdaq : APLS managementApellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical OfficerApellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that leading retina specialist Caroline Baumal, M.D., has joined Apellis as chief medical officer. Dr. Baumal replacesRHEA-AIneutral
01/03/23 7:00 AMNasdaq : APLS conferencesApellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare ConferenceApellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will present at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:00 a.m.RHEA-AIneutral